Kornimate/medical-research-clean huggingface dataset:
evaluation of long-term effect of resonator therapy on parkinson's disease (pd)

Conditions: Parkinson's Disease

Summary: an extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic parkinson's disease.


Eligibility criteria:
inclusion criteria: * prior participation in pico-tesla pilot studies: nct00779155 \& nct00863226 * willing and able to abstain from partaking in non-essential new treatments for parkinson's disease symptoms during the course of participation of the study. * will and able to abstain from all non-essential new medications that could affect pd and/or any of its associated symptoms for the duration of the study. * willing to notify the investigator right away of any changes in medication use or therapies that is prescribed and deemed necessary by the subjects physicians. * adequate contraceptive measures for female subjects * capable of giving full written informed consent exclusion criteria: * not a participant in irc#'s 07102 or 07021 * no active brain tumors, strokes, hydrocephalus * chronic pain not associated with pd * any other condition which might prevent subject from comfortably sitting for 1.5 hours * consumption of medications that can produce parkinsonism type symptoms * major psychiatric disturbance * epilepsy * hiv and other autoimmune disorders * cancer within last 2 years * history of ect * diabetic neuropathy * uncontrolled htn * advanced pulmonary disease * known heart conditions such as repetitive history of cardiac arrythmias * previous surgeries for pd * prosthetics comprised of ferrous materials * stents, only where there is also cardiac arrythmias, chf, advanced valvular stenosis, unstable vital signs, extensive ischemic damage to heart muscle as a result of one or more heart attacks. * pacemakers * uncontrolled, unstable, or untreated medical illnesses which might potentially significantly affect the patient's health in the opinion of the investigator * consumption of more than 21 alcoholic drinks per week * pregnant, breast feeding or planning pregnancy * developmental disability or cognitive impairment * inability to maintain regular medication regime * inability to abstain from partaking in new non-essential pd tx., or medications * not willing to report physician mandated changes in medication and/or treatment
curative image guided radiotherapy for prostate cancer

Conditions: Prostatic Neoplasms

Summary: the clinical importance of cone beam computer tomography based image guided radiotherapy (ct- igrt) has not been established. the primary aim of the present trial is to investigate whether ct- igrt and consequently reduced safety margins reduces the rectal side effects from curative, high dose radiotherapy in prostate cancer. any impact of the reduced planning target volume in the ct- igrt arm on biochemical freedom from disease will be evaluated as secondary outcome. an open randomised phase iii trial. the included men will be randomised to receive curative radiotherapy to 78 gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm) or 78 gy in 39 fractions with daily ct position verification and reduced safety margins (7mm).


Eligibility criteria:
inclusion criteria: * biopsy confirmed adenocarcinoma of prostate * no evidence of nodal or distant metastases (n0m0) * intermediate or high risk based on t stage, psa level and gleason score * informed consent exclusion criteria: * previous treatment for cancer last 5 years, except basal cell carcinoma of skin * any previous radiotherapy, except kv or electron treatment of skin tumors outside the pelvis * metallic hip joint replacement * pre-existing intestinal or genitourinary disease with increased risk of side effects * any pre-existing condition making the patient unsuitable for radiotherapy * any pre-existing condition making the patient unsuitable for hormonal therapy * any pre-existing condition making the patient unsuitable for mri. * alat, gt, alp, creatinin \> 1.5 x upper normal limit

Keywords: radiotherapy, image-guided adverse effects position verification safety margins
a study of the cd73 inhibitor ly3475070 alone or in combination with pembrolizumab in participants with advanced cancer

Conditions: Advanced Cancer

Summary: the reason for this study is to see if the cd73 inhibitor ly3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.


Eligibility criteria:
inclusion criteria: * participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer * participants must have stopped other forms of treatment for the cancer * in the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. for certain tumor types, the result of a test on the tumor sample may exclude the participant from the study * participants must not be pregnant, and must agree to use birth control * participants must have progressed through or be intolerant to therapies with known clinical benefit exclusion criteria: * participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled hiv, autoimmune disease, active hepatitis b or c virus infection or using corticosteroids * participant must not have cancer that has spread to the brain * participant must not have received a vaccine within the last 30 days * participant must not have had bowel obstruction within the last 6 months, or intestinal surgery * participant must not have an infection that is currently being treated

Keywords: triple negative breast cancer pancreatic cancer non-small cell lung cancer renal cell carcinoma, clear cell cutaneous melanoma castrate resistant prostate cancer epithelial ovarian cancer metastatic cancer
value of liquid potassium magnesium citrate in controlling hypertension

Conditions: Hypertension

Summary: liquid potassium-magnesium citrate (kmgcit) as a pharmaceutical formulation will lower blood pressure among patients with pre- or stage i hypertension on their customary diet.

in this protocol, the investigators want to explore whether kmgcit taken during a customary dietary setting, might serve as a "surrogate" for the dietary approaches to stop hypertension (dash) diet to lower blood pressure. this study has obvious biomedical importance. lifestyle modifications are often recommended for pre- or stage i hypertension. the dash diet is such a modification that has been shown to be effective. however, this diet is costly and difficult to adhere to long-term. if kmgcit were shown to be effective in lowering blood pressure, it would provide a safe and convenient alternative to the dash diet.

Eligibility criteria:
inclusion criteria: * men or women \> 21 years of age * any race/ethnicity * pre- or stage i hypertension (bp \>= 120/80 and \<= 159/99) exclusion criteria: * diabetes mellitus * renal impairment (serum creatinine \> 1.4 mg/dl) * any heart diseases such as congestive heart failure or sustained arrhythmia * chronic nsaid use * treatment with diuretics * gastroesophageal reflux disease (gerd) requiring treatment with acid reducing agents or antacid more than once a week * esophageal-gastric ulcer * chronic diarrhea * hyperkalemia (serum \> 4.6 meq/l for patients on angiotension-converting-enzyme (ace) inhibitors or angiotensin receptor blockers (arbs), serum k \> 5.0 meq/l for patient not on ace inhibitors or arbs) * abnormal liver function test (aspartate transaminase (ast) or alanine transaminase (alt) above upper limit of normal range) * subjects who require any potassium supplement on a regular basis from any reasons * pregnancy * history of major depression, bipolar disorder, or schizophrenia
a study to compare treating hypertension with valsartan 160 mg to valsartan 320 mg

Conditions: Hypertension

Summary: the purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of blood pressure reduction in a patient population of mild to moderate hypertensives


Eligibility criteria:
inclusion criteria: * • male or female age between 18-80 years of age, inclusive * diagnosed at enrollment (visits 2) to be mild to moderate hypertensive with a msdbp \>= 95 and =\< 109 mmhg for non treated patients. * previously treated patients should have a msdbp =\ = 95 and =\< 109 mmhg at visit 2. * written informed consent to participate in the study prior to any study procedures * ability to communicate and comply with all study requirements exclusion criteria: * severe hypertension (grade 3 of who classification; \>= 110 mmhg diastolic and/or \>= 180 mmhg systolic). * malignant hypertension * inability to discontinue all prior anti-hypertensive medications safely for a period of 2 weeks, as required by the protocol. * known history of proteinuria (greater than 0.3 gram per day) * female patients who are not either post-menopausal for one year or surgically sterile, and who are not using effective contraceptive methods such as barrier method with spermicidal or an intra-uterine device. oral contraceptive use is not allowed. * known keith-wagener grade iii or iv hypertensive retinopathy. * history of hypertensive encephalopathy or cerebrovascular accident at anytime prior to visit 1. * transient ischemic cerebral attack during the last 12 months prior to visit 1.

Keywords: hypertension valsartan
using an electronic personal health record to empower patients with hypertension

Conditions: Hypertension

Summary: project summary: an electronic personal health record (ephr) could maximize patient/clinician collaboration and consequently improve patient self-management and related health outcomes. the purpose of the proposed project is to examine the feasibility, acceptability, and impact of an ephr that has been modified using a patient- and family-centered approach and incorporates the experiences, perspectives, and insights of patients and family members actually using the system. comparison of patients with the ephr intervention to a group of "care as usual" patients will be performed. the investigators specific aims are: (1) to improve the application of patient- and family-centered care elements in an existing ephr, based on feedback from a pilot study of patients and their families. the modified ephr will be tested in a pilot group of patients with hypertension and their families. (2) to implement and test the effectiveness of the modified ephr with patients being treated for hypertension by a team of physicians, mid-level practitioners, nurse clinicians, and support staff in two ambulatory settings. outcome measures will include patient activation and perception of care, quantifiable biological markers, patient-physician communication, and congruence of treatment with guidelines, particularly medication management; (3) to monitor the shift in provider and support staff awareness and incorporation of patient- and family-centered care as a result of implementation of the ephr using questionnaires and focus groups. if successful, this ephr could be implemented in additional locations in the southeast.


Eligibility criteria:
inclusion criteria: * age 21 * hypertension * referral by physician exclusion criteria: * age over 80 * no hypertension * too ill to participate

Keywords: personal health records
study to assess the tolerability, safety and efficacy of an adapted gut cleansing solution in routine colon cleansing prior to colonoscopies

Conditions: Colon Cancer

Summary: it is particularly important that thorough gut cleansing is achieved prior to the colonoscopy for the procedure to be successful. polyethylene glycol plus electrolyte (peg+e) solutions are well established as safe and effective agents for gut cleansing and norgine has successfully developed a low volume (2 litre) peg+e gut lavage solution. the efficacy and safety of this solution is similar to the standard 4 litre peg+e, but with improved patient acceptance. tolerance, acceptability and satisfaction with the cleansing agent plays an important role in subjects' compliance with gut preparation procedure. the study medication nrl0706 is identical to the peg+e-containing gut lavage solution commonly used in clinical practice, with the exception that the flavour has been modified from lemon to orange. this study is to investigate the tolerability, acceptability, safety and efficacy of a single dose of nrl0706 (moviprep orange) in subjects without gastrointestinal symptoms undergoing colonoscopy for colon cancer screening.


Eligibility criteria:
inclusion criteria: * the subject's written informed consent must be obtained prior to inclusion. * male or female ambulatory subjects aged between 40 to 75 years undergoing a complete colonoscopy for colon cancer screening. * no history of significant gastrointestinal diseases, including gastrointestinal obstruction and perforation or acute symptoms requiring a colonoscopy procedure. * willing to undergo a colonoscopy for colon cancer screening. * willing, able and competent to complete the entire procedure and to comply with study instructions. * females of childbearing potential must employ an adequate method of contraception. exclusion criteria: * history of gastric emptying disorders * history of ileus, toxic megacolon, gastrointestinal obstruction and colonic perforation * history of phenylketonuria * known glucose-6-phosphate dehydrogenase deficiency * known hypersensitivity to macrogol 3350, sodium sulphate or ascorbic acid/ sodium ascorbate * history of colonic resection * requirement for permanent medication and associated stable serum concentrations (e.g. neuroleptic drugs) * presence of congestive heart failure (nyha iii + iv) * acute life-threatening cardiovascular disease * documented history of severe renal insufficiency * application of any unlicensed medication within the previous 3 months or participation in any other research study in the last 3 months * females who are pregnant, nursing or planning a pregnancy. females of child bearing potential not using reliable methods of contraception * subjects who the investigator feels would not be compliant with the requirements of the trial
s0701, trial of three antibiotic regimens to eradicate helicobacter pylori (h. pylori)

Conditions: Helicobacter Pylori Infection

Summary: the purpose of this study is to compare the effectiveness of three different antibiotic regimens against helicobacter pylori (h. pylori).

prevention of gastric cancer through eradication of h. pylori is one of the most promising strategies to reduce the global impact of cancer in the near term. our long-term goal is to prevent gastric cancer by developing and validating an effective, simple, and low-cost approach to eradication of h. pylori. our immediate goal, therefore, is to conduct a randomized study to compare the effectiveness of three different drug regimens for h. pylori infection. the three study arms are: standard therapy - 14 day, 3-drug regimen of lansoprazole, amoxicillin and clarithromycin (pacx14); concomitant therapy - 5 day, 4-drug regimen of lansoprazole, amoxicillin, clarithromycin, metronidazole (pacmx5); sequential therapy - 10 day, 4-drug regimen of lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (pax5/pcmx5).

Eligibility criteria:
inclusion criteria: * positive urea breath test documenting h. pylori infection * age 21 - 65 years * no known allergies to study drugs * only member of household participating in study * no known medical conditions (other than h. pylori) that would preclude or require antibiotic therapy * patients must be willing to discontinue alcohol use for 15 days (maximum duration of treatment plus one day) * patients must be willing to discontinue use of antacids for duration of study treatment * patients must not have used proton pump inhibitors (ppi) within 30 days of registration. patients also must be willing to stop using non-study provided ppis until the completion of the 6 week follow-up contact. * patients must not have been treated with antibiotics for h. pylori in the past and must not have taken any other antibiotics within 30 days of registration. * patients must be willing to return for 2 follow-up visits: 6 weeks after randomization following completion of treatment \& 1 year after randomization * patients must be willing to allow submission of blood for assays of serum markers of bacterial virulence and host genetic susceptibility and environmental factors and provide consent for use of specimens. exclusion criteria: * current use of anti-retroviral therapy for hiv or aids * diagnosed congestive hear failure * renal failure requiring dialysis * diagnosed hepatic failure resulting in hyperbilirubinemia * any current or prior malignancy except: adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated stage i or stage ii cancer from which the patient has been disease free for 5 years * pregnancy or nursing mothers

Keywords: h. pylori
trial to define the safety and tolerability of sgn-40, rituximab, and gemcitabine in patients with dlbcl

Conditions: Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin

Summary: the purpose of this study is to determine safety and tolerability of combination therapy of sgn-40 with gemcitabine and rituximab for the treatment of lymphoma. this study is also intended to estimate how well your disease responds to this treatment.


Eligibility criteria:
inclusion criteria: * have a histologic diagnosis of dlbcl, including transformed histology and follicular grade 3 disease. * must have at least one site of biopsy-proven disease demonstrating both of the following: bidimensional measurable disease with the longest axis \>= 1.5cm by radiographic imaging or positive fdg-pet scan at baseline. * patients with dlbcl and who have either relapsed, refractory, or progressive disease following salvage therapy, or relapsed, refractory, or progressive disease following initial therapy and be medically unfit to receive aggressive therapy. * either fresh or archived tumor specimen must be available. exclusion criteria: * documented history within 6 months of registration of a cerebral vascular event, unstable angina, myocardial infarction, or cardiac symptoms. * patients who have received allogeneic stem cell transplant. * patients with evidence of another invasive primary malignancy within the past three years other than non-melanoma skin cancer, cervical carcinoma in situ, in situ carcinoma of the breast, or fully resected prostate cancer with normal psa within 8 weeks of registration. * patients with any active systemic viral, bacterial, or fungal infection requiring intravenous anti-infectives within 4 weeks prior to first dose of study drug. * patients with a history or clinical evidence of leptomeningeal or central nervous system (cns) lymphoma.

Keywords: antigens, cd40 antibodies, monoclonal combined modality therapy lymphoma, large b-cell, diffuse lymphoma, non-hodgkin hematologic diseases immunoproliferative disorders lymphatic diseases lymphoproliferative disorders lymphoma
p53 gene combined with radio- and chemo-therapy in treatment of unresectable locally advanced head and neck cancer

Conditions: Advanced Head and Neck Cancer

Summary: the objectives of this study are to investigate the efficacy and safety of rad-p53 gene combined with radio- and chemo-therapy vs. radio- and chemo- therapy only in treatment of unresectable, locally advanced head and neck cancer. this is a phase 2, open labeled, and active-controlled study.

to evaluate benefits of rad-p53) gene therapy combined with radio- and chemo-therapy in treatment of unresectable, locally advanced head and neck cancer, total of 60 patients with above condition will be randomly assigned to two groups: the experiment group (eg) and the control group (cg). the eg received multi-point injections of rad-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10\^12 viral particles (vp) in a 21-days cycle. both eg and cg were given radiotherapy at a total dose of 60 gy and chemotherapy (cisplatin 100 mg/m2 iv on days 1 plus paclitaxel 30 mg/m2 iv on day 1, 8 and 15). the patients will be treated until disease progression, withdrawal from study, or untolerated adverse events. study endpoints are efficacy (progression-free survival, overall survival) and safety variables.

Eligibility criteria:
inclusion criteria: 1. histopathologically diagnosed head and neck cancer; 2. unresectable, locally advanced; 3. 18 years or older; 4. with an eastern cooperative oncology group (ecog) score of 0-2; 5. with normal tests of hemogram, blood coagulation, liver and kidney function; 6.signed the informed consent form. exclusion criteria: 1. serious blood coagulation disorder, bleeding tendency, platelet \< 6 \* 1000000000/l; 2. have serious heart, lung function abnormalities or severe diabetes patients; 3. active infection; 4. severe atherosclerosis; 5. aids patients; 6. serious thrombotic or embolic events within 6 months; 7. renal insufficiency requiring hemodialysis or peritoneal dialysis; 8. pregnant or lactating women; 9. mental disorder or disease.

Keywords: p53 gene therapy head and neck cancer
a multi-center study of apixaban(approach)

Conditions: Evaluate the Safety and Efficacy of Apixaban

Summary: the aim of the study is to enroll approximately 200 cases from 10 research centers nationwide, completed left atrial appendage occlusion (laao) successfully, and give apixaban (5 mg bid) postoperatively.


Eligibility criteria:
inclusion criteria: * age between 18 to 85 years; * understand the purpose of the trial, sign the informed consent form voluntarily * successful surgery (no pericardial effusion, pericardial tamponade, or device displacement during operation; no pericardial effusion before discharge), meet cost standard during operation. * in accordance with the indications for left atrial appendage occlusion: cha2ds2-vas2 score≥2 points and/or has-bled score≥3 points * unable or unwilling to take oral anticoagulants * life expectancy≥1 year exclusion criteria: * history of previous cardiac surgery (valve disease, cardiomyopathy, severe coronary occlusion); * inability to tolerate trans-esophageal echocardiography; * preoperative trans-esophageal echocardiography suggests thrombus in left atrial appendage/left atrial; * patients with severe renal insufficiency (creatinine clearance rate\<15ml/min); * patients with liver disease accompanied by abnormal blood coagulation and clinically related bleeding risks; * clinically significant active bleeding; * the baseline platelet count is severely reduced: plt≤50\*10\^9/l; * severe cardiac insufficiency (preoperative transthoracic echocardiography indicated lvef \<35%; uncontrolled heart failure (nyha iv)) * allergy or contraindication to anticoagulant drugs such as aspirin, clopidogrel, apixaban, etc .; * serious heart valve disease or other structural abnormalities need do elective surgical treatment; or severe coronary heart disease require limited-term intervention; * less than 45kg or more than 100kg. * take strong cyp3a4 and p-gp inhibitors (including pyrrole antifungal drugs, hiv protease inhibitors, etc.) for systemic treatment; * patients with other diseases besides atrial fibrillation (such as after mechanical valve replacement, spontaneous or recurrent venous thromboembolism, etc.) need anticoagulation treatment; * unsuccessful surgery (serious pericardial tamponade, massive bleeding and other life-threatening complications occur within 3 days after left atrial appendage closure); * pregnancy or lactation; * participating in other uncompleted clinical trials; * investigator considers inappropriate subjects.